Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
Details of the presentation are as follows:
- Title: A Randomized Double-Masked Phase 2 Clinical Trial of NS2 Ophthalmic Solution in Allergic Conjunctivitis
- Date: Saturday November 12that
Moscone West Convention Center- Monitor No. 8
- Presented by:
David Clark, M.D., M.R.C.P., A.F.P.M, Chief Medical Officer of Aldeyra Therapeutics
- Poster #: P316
The data represent the first demonstration of the clinical efficacy of aldehyde trapping in human disease, and support the continued development of ADX-102 in allergic conjunctivitis and other inflammatory diseases.
About Allergic Conjunctivitis
Allergic conjunctivitis is a common allergic disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, lid swelling and redness.
Cautionary statement regarding forward-looking statements
Aldeyra cautions investors that any forward-looking statements or projections made by Aldeyra, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Annual Report on Form 10-K for the year ended
Tel: +1 781-761-4904 Ext. 205
News Provided by Acquire Media